PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2007 | 2 | 1 | 47-65
Tytuł artykułu

Management patterns of thrombosis prophylaxis and related costs in hip and knee replacement in Germany

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
The objective of the study was to depict treatment strategies, health care utilisation and cost evaluation of hip and knee replacement surgery in Germany, with a particular emphasis on thrombosis prophylaxis (TP) for the prevention of deep vein thrombosis (DVT). In this multi-centre prospective cohort study, medical record data (socio-demographics, risk factors for thrombosis, thrombosis prophylaxis, course of hospital stay) were collected for patients undergoing either total hip replacement (THR) or total knee replacement (TKR). One and three months post-operatively, post-operative outcomes and health care resource use were documented by patient and physician questionnaires. A total of 309 patients participated in the study (59% female, mean age 66 [SD 10] years). Parenteral anticoagulation was administered for a mean of 38 (SD 16) days. 27 (9%) patients received subsequent oral anticoagulation for a mean of 38 (SD 21) additional days. Symptomatic DVT was reported by four (1.3%) patients. Mean overall direct costs associated with surgery from baseline to 3 months were EUR 11 264 (median 11 564, SD 2 481). Hospital and rehabilitation accounted for 97% of direct costs; costs for medications, physical therapy, physician office visits, out-of-pocket expenses, as well as complication costs accounted for an additional 3% of direct costs. Within these direct costs, a mean of EUR 348 (SD 361) was related to thrombosis prophylaxis, accounting for 3% of direct costs. Mean overall cost was EUR 11 926 (SD 2 481), including 6% indirect costs of productivity loss. Extended thrombosis prophylaxis was observed in the usual care setting of the study and associated with low incidence of symptomatic DVT. Thrombosis prophylaxis is - within the considerable economic burden of joint replacement surgery - a relatively small cost component.
Wydawca

Czasopismo
Rocznik
Tom
2
Numer
1
Strony
47-65
Opis fizyczny
Daty
wydano
2007-03-01
online
2007-03-01
Twórcy
  • Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, 10098, Berlin, Germany, doreen.mcbride@charite.de
  • Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, 10098, Berlin, Germany
  • Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, 10098, Berlin, Germany
  • Department of Orthopaedics and Rheumatology, University Hospital Giessen and Marburg, 35043, Marburg, Germany
  • Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, 10098, Berlin, Germany
Bibliografia
  • [1] G. Agnelli and C. Becattini: “Clinical and economic aspects of managing venous thromboembolism in the outpatient setting”, Semin. Hematol., Vol. 38(2), Suppl 5, (2001), pp. 58–66. http://dx.doi.org/10.1016/S0037-1963(01)90099-X[Crossref]
  • [2] T.M. Hyers, G. Agnelli, R.D. Hull, J.G. Weg, T.A. Morris, M. Samama and V. Tapson: “Antithrombotic therapy for venous thromboembolic disease 1998”, Chest, Vol. 114(5), (1998), pp. 561S–578. [WoS]
  • [3] T.M. Hyers, G. Agnelli, R.D. Hull, J.G. Weg, T.A. Morris, M. Samama and V. Tapson: “Antithrombotic therapy for venous thromboembolic disease 1998”, Chest, Vol. 114(5), (1998), pp. 561S–5578S. [WoS]
  • [4] P.K. Schädlich, J.G. Brecht and E. Huppertz: “Treatment costs of venous thromboembolic complications in acutely ill medical patients in Germany”, Perfusion, Vol. 16(4), (2003), pp. 141–152.
  • [5] W.H. Geerts, J.A. Heit, G.P. Clagett, G.F. Pineo, C.W. Colwell, F.A. Anderson, Jr. and H.B. Wheeler: “Prevention of venous thromboembolism 2001”, Chest, Vol. 119(1), Suppl, (2001), pp. 132S–175S. http://dx.doi.org/10.1378/chest.119.1_suppl.132S[Crossref]
  • [6] E.A. Salvati, V.D. Pellegrini, Jr., N.E. Sharrock, P.A. Lotke, D.W. Murray, H. Potter and G.H. Westrich: “Recent advances in venous thromboembolic prophylaxis during and after total hip replacement”, J. Bone Joint Surg. Am., Vol. 82(2), (2000), pp. 252–270.
  • [7] T.M. Hyers, G. Agnelli, R.D. Hull, J.G. Weg, T.A. Morris, M. Samama and V. Tapson: “Antithrombotic therapy for venous thromboembolic disease 1998”, Chest, Vol. 114(5), (1998), pp. 561S–578S. [WoS]
  • [8] W.H. Geerts, J.A. Heit, G.P. Clagett, G.F. Pineo, C.W. Colwell, F.A. Anderson, Jr. and H.B. Wheeler: “Prevention of venous thromboembolism 2001”, Chest, Vol. 119(1), Suppl, (2001), pp. 132S–175S. http://dx.doi.org/10.1378/chest.119.1_suppl.132S[Crossref]
  • [9] D.N. Mohr, M.D. Silverstein, D.M. Ilstrup, J.A. Heit and B.F. Morrey: “Venous thromboembolism associated with hip and knee arthroplasty: current prophylactic practices and outcomes”, Mayo Clin. Proc., Vol. 67(9) (1992), pp. 861–870.
  • [10] D.W. Murray, A.R. Britton and C.J. Bulstrode: “Thromboprophylaxis and death after total hip replacement”, J. Bone Joint Surg. Br., Vol. 78(6), (1996), pp. 863–870. http://dx.doi.org/10.1302/0301-620X78B6.6714[Crossref]
  • [11] S. Ansari, D. Warwick, C.E. Ackroyd and J.H. Newman: “Incidence of fatal pulmonary embolism after 1,390 knee arthroplasties without routine prophylactic anticoagulation, except in high-risk cases”, J. Arthroplasty, Vol. 12(6), (1997), pp. 599–602. http://dx.doi.org/10.1016/S0883-5403(97)90131-5
  • [12] W.H. Geerts, J.A. Heit, G.P. Clagett, G.F. Pineo, C.W. Colwell, F.A. Anderson, Jr. and H.B. Wheeler: “Prevention of venous thromboembolism 2001”, Chest, Vol. 119(1), Suppl, (2001), pp. 132S–175S. http://dx.doi.org/10.1378/chest.119.1_suppl.132S[Crossref]
  • [13] J. Edelsberg, D. Ollendorf and G. Oster: “Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics”, Am. J. Health Syst. Pharm., Vol. 58, Suppl. 2, (2001), pp. S4–13.
  • [14] B. Kirchhof, A.J. Palmer, V.V. Kakkar and R. Bergemann: “Langzeitfolgen der tiefen Beinvenenthrombose: ihre wirtschaftliche Bedeutung”, Gesundh. ökon. Qual. Manag., Vol. 2, (1997), pp. 40–44.
  • [15] J.S. Ginsberg, F. Turkstra, H.R. Buller, B. MacKinnon, D. Magier and J. Hirsh: “Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study”, Arch. Intern. Med., Vol. 160(5), (2000), pp. 669–672. http://dx.doi.org/10.1001/archinte.160.5.669[Crossref]
  • [16] E. Bernardi and P. Prandoni: “The post-thrombotic syndrome”, Curr. Opin. Pulm. Med., Vol. 6(4), (2000), pp. 335–342. http://dx.doi.org/10.1097/00063198-200007000-00015[Crossref]
  • [17] AOK-Verband: Zugelassene Krankenhäuser: Betriebsstrukturen und Vergütungsregelungen 2003, AOK-Verlag, 2003.
  • [18] Verband der Angestellten-Krankenkassen: “Vergütungsliste”, (2002), http://www.vdak.de/.
  • [19] Multimedia GmbH: “Gelbe Liste Pharmindex 2003.” http://www.gelbe-liste.de/ (2003, http://www.gelbe-liste.de/.
  • [20] C. Juhra, N. Roeder and N. Loskamp: “Thromboseprophylaxe im Zeitalter der DRGs”, Vascular Care, Vol. 5, (2003), pp. 56–61.
  • [21] B. Raming: Kosteneffektivität der Thromboseprophylaxe mit niedermolekularem Heparin bei Hüft-und Kniegelenksersatzoperationen, Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie der Medizischen Fakultät der Charité-Universitätsmedizin Berlin, 2004.
  • [22] “Einheitlicher Bewertungsmaßstab”, (2003), http://www.e-bis.de/ebm/Default.htm.
  • [23] Verband Deutscher Rentenversicherungsträger, (2002), http://www.vdr.de/internet/vdr/statzr.nsf/($URLRef)/57D0E2AA78C75849C1256A390043F7AD.
  • [24] Deutsche Gesellschaft für Chirurgie: “Leitlinien zur stationären und ambulanten Thromboembolie-Prophylaxe in der Chirurgie 2000”, AWMF-Leitlinien-Register Nr.003/001 Grundlagen der Chirurgie, Beilage zu den Mitteilungen der Dt.Ges.f.Chirurgie, (2000), http://www.awmf-leitlinien.de/.
  • [25] E.A. Salvati, V.D. Pellegrini, Jr., N.E. Sharrock, P.A. Lotke, D.W. Murray, H. Potter and G.H. Westrich: “Recent advances in venous thromboembolic prophylaxis during and after total hip replacement”, J. Bone Joint Surg. Am., Vol. 82(2), (2000), pp. 252–270.
  • [26] M.H. Prins and J. Hirsh: “A comparison of general anesthesia and regional anesthesia as a risk factor for deep vein thrombosis following hip surgery: a critical review”, Thromb. Haemost., Vol. 64(4), (1990), pp. 497–500.
  • [27] G.P. Westert, R.J. Lagoe, I. Keskimaki, A. Leyland and M. Murphy: “An international study of hospital readmissions and related utilization in Europe and the USA”, Health Policy, Vol. 61(3), (2002), pp. 269–278. http://dx.doi.org/10.1016/S0168-8510(01)00236-6[Crossref]
  • [28] E. Sheehan, M. Neligan and P. Murray: “Hip arthroplasty, changing trends in a national tertiary referral centre”, Ir. J. Med. Sci., Vol. 171(1), (2002), pp. 13–15. http://dx.doi.org/10.1007/BF03168932[Crossref]
  • [29] D.A. Ollendorf, M. Vera-Llonch and G. Oster: “Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients”, Am. J. Health Syst. Pharm., Vol. 59(18), (2002), pp. 1750–1754.
  • [30] “Spitzenverbände der Krankenkassen, Verband der privaten Krankenversicherung, Deutsche Krankenhausgesellschaft”, Internet, (2005), http://www.g-drg.de/.
  • [31] B. Kladny, C. Albrecht, I. Haase and B. Swoboda: “[Inpatient rehabilitation of patients following total hip replacement-a study using the Harris hip score]”, Z. Orthop. Ihre Grenzgeb., Vol. 139(6), (2001), pp. 536–540.
  • [32] E.L. Hannan, J.F. O’Donnell, H. Kilburn, Jr., H.R. Bernard and A. Yazici: “Investigation of the relationship between volume and mortality for surgical procedures performed in New York State hospitals”, JAMA, Vol. 262(4) (1989), pp. 503–510. http://dx.doi.org/10.1001/jama.262.4.503[Crossref]
  • [33] W.H. Geerts, J.A. Heit, G.P. Clagett, G.F. Pineo, C.W. Colwell, F.A. Anderson, Jr. and H.B. Wheeler: “Prevention of venous thromboembolism 2001”, Chest, Vol. 119(1), Suppl, (2001), pp. 132S–175S. http://dx.doi.org/10.1378/chest.119.1_suppl.132S[Crossref]
  • [34] A.T. Cohen, C.S. Bailey, R. Alikhan and D.J. Cooper: “Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty-a meta-analysis”, Thromb. Haemost., Vol. 85(5), (2001), pp. 940–941.
  • [35] G. Agnelli and C. Becattini: “Clinical and economic aspects of managing venous thromboembolism in the outpatient setting”, Semin. Hematol., Vol. 38(2), Suppl 5, (2001), pp. 58–66. http://dx.doi.org/10.1016/S0037-1963(01)90099-X[Crossref]
  • [36] M. Marchetti, N.L. Liberato, N. Ruperto and G. Barosi: “Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement”, Haematologica, Vol. 84(8), (1999), pp. 730–737.
  • [37] R.H. White and M.C. Henderson: “Risk factors for venous thromboembolism after total hip and knee replacement surgery”, Curr. Opin. Pulm. Med., Vol. 8(5), (2002), pp. 365–371. http://dx.doi.org/10.1097/00063198-200209000-00004[Crossref]
  • [38] J.A. Heit, M.D. Silverstein, D.N. Mohr, T.M. Petterson, W.M. O’Fallon and L.J. Melton, III: “Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study”, Arch. Intern. Med., Vol. 160(6), (2000), pp. 809–815. http://dx.doi.org/10.1001/archinte.160.6.809[Crossref]
  • [39] Deutsche Gesellschaft für Chirurgie: “Leitlinien zur stationären und ambulanten Thromboembolie-Prophylaxe in der Chirurgie 2003”, AWMF-Leitlinien-Register Nr.003/001 Grundlagen der Chirurgie, Beilage zu den Mitteilungen der Dt.Ges.f.Chirurgie, (2003), http://www.awmf-leitlinien.de/.
  • [40] J. Edelsberg, D. Ollendorf and G. Oster: “Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics”, Am. J. Health Syst. Pharm., Vol. 58,Suppl 2, (2001), pp. S4–13.
  • [41] G. Agnelli and C. Becattini: “Clinical and economic aspects of managing venous thromboembolism in the outpatient setting”, Semin. Hematol., Vol. 38(2), Suppl 5, (2001), pp. 58–66. http://dx.doi.org/10.1016/S0037-1963(01)90099-X[Crossref]
  • [42] R. Hansen, V. Bruchhausen and R. Rychlik: “Thromboembolie - Risiken, Ereignisse und Kosten der modernen Prophylaxe mit niedermolekularen Heparinen”, Fortschritte der Medizin, Vol. 117, (1999), pp. 155–58.
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_s11536-007-0005-7
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.